Tanya Chin
Family Medicine · Hendersonville, NCNPI 1982605895
Payments from drug & device makers
Across 103 payments — averaging $16.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$244
- Pfizer$202
- GSK$189
- Amgen$176
- Astellas Pharma US Inc$153
- AstraZeneca$141
- plus $594 from 15 others
What the payments were for
- Food & beverage$1,700100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $244 |
| Pfizer | 16 | $202 |
| GSK | 12 | $189 |
| Amgen | 10 | $176 |
| Astellas Pharma US Inc | 7 | $153 |
| AstraZeneca | 9 | $141 |
| Johnson & Johnson | 9 | $135 |
| AbbVie | 5 | $86 |
| Lilly USA, LLC | 4 | $58 |
| Novartis | 3 | $51 |
| Abbott | 2 | $43 |
| Medtronic | 1 | $39 |
| Dexcom, Inc. | 2 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Bayer | 1 | $22 |
| Inari Medical, Inc. | 1 | $22 |
| Nevro Corp. | 1 | $19 |
| Irhythm Technologies, Inc. | 1 | $16 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $16 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Promius Pharma LLC | 1 | $12 |
How this compares
$1,700 in reported general payments places this provider in the 75th percentile of 3,444 family medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $135,823 |
| MounjaroTirzepatide | 41 | $58,284 |
| JardianceEmpagliflozin | 35 | $52,513 |
| EliquisApixaban | 54 | $39,013 |
| Tresiba Flextouch U-100Insulin Degludec | 29 | $19,120 |
| FarxigaDapagliflozin Propanediol | 22 | $17,658 |
| XareltoRivaroxaban | 16 | $17,035 |
| Repatha SureclickEvolocumab | 12 | $8,596 |
| MyrbetriqMirabegron | 13 | $8,349 |
| SynthroidLevothyroxine Sodium | 81 | $7,990 |
| NexletolBempedoic Acid | 20 | $7,841 |
| Atorvastatin Calcium | 567 | $5,675 |
| Ezetimibe | 98 | $3,912 |
| Levothyroxine Sodium | 349 | $3,289 |
| Valsartan | 120 | $3,164 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $244 | $135,82398 claims |
| Lilly USA, LLCMounjaro | $58 | $58,28441 claims |
| PfizerEliquis | $202 | $39,01354 claims |
| AstraZenecaFarxiga | $141 | $17,65822 claims |
| Johnson & JohnsonXarelto | $135 | $17,03516 claims |
| Astellas Pharma US IncMyrbetriq | $153 | $8,34913 claims |
| AbbVieSynthroid | $86 | $7,99081 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,444 family medicine providers in North Carolina.
Other family medicine in Hendersonville
- David LamondHendersonville$169K
- Barton WilliamsWilmington$17.3M
- Alexander MurrayGreensboro$13M
- Arin PiramzadianJacksonville$13M
- Jonathan WilsonHickory$12.7M
- George RaadCharlotte$7.7M
- Cecil FarringtonSalisbury$6.4M
- Christian MartinShelby$5.4M
- John EarlHickory$4.7M
- Patrick MorganteHavelock$4.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.